Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

Kelsey Klute, Eleni Nackos, Shinsuke Tasaki, Daniel P. Nguyen, Neil H. Bander, Scott T. Tagawa

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and limiting toxicity to normal tissue. Microtubules represent a validated oncologic target in a range of tumor types, with a number of anti-microtubule targeting cytotoxic drugs approved for cancer use. The systemic use of potent microtubule-binding agents is limited by their effects in normal cells, which leads to toxicity including myelosuppression and peripheral neuropathy. Linking these agents to monoclonal antibodies may limit toxicity to normal tissues and increase drug concentration in target tissues, also allowing the use of more potent agents which would be too toxic to administer in their unbound form. Two such ADCs have been approved for clinical use and many others are in development. Here we review the characteristics of each of the ADC components that have led to efficacious therapies and discuss some of the tubulin inhibitor-based ADCs in development for cancer therapy.

Original languageEnglish (US)
Pages (from-to)2227-2236
Number of pages10
JournalOncoTargets and Therapy
Volume7
DOIs
StatePublished - Dec 3 2014

Fingerprint

Microtubules
Pharmaceutical Preparations
Antibodies
Monoclonal Antibodies
Neoplasms
Tubulin Modulators
Therapeutics
Poisons
Peripheral Nervous System Diseases
Drug Delivery Systems
Drug Therapy

Keywords

  • Antibody–drug conjugate
  • Microtubule inhibitor
  • Monoclonal antibody

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Klute, K., Nackos, E., Tasaki, S., Nguyen, D. P., Bander, N. H., & Tagawa, S. T. (2014). Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 7, 2227-2236. https://doi.org/10.2147/OTT.S46887

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. / Klute, Kelsey; Nackos, Eleni; Tasaki, Shinsuke; Nguyen, Daniel P.; Bander, Neil H.; Tagawa, Scott T.

In: OncoTargets and Therapy, Vol. 7, 03.12.2014, p. 2227-2236.

Research output: Contribution to journalReview article

Klute, K, Nackos, E, Tasaki, S, Nguyen, DP, Bander, NH & Tagawa, ST 2014, 'Microtubule inhibitor-based antibody–drug conjugates for cancer therapy', OncoTargets and Therapy, vol. 7, pp. 2227-2236. https://doi.org/10.2147/OTT.S46887
Klute, Kelsey ; Nackos, Eleni ; Tasaki, Shinsuke ; Nguyen, Daniel P. ; Bander, Neil H. ; Tagawa, Scott T. / Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. In: OncoTargets and Therapy. 2014 ; Vol. 7. pp. 2227-2236.
@article{a6911e73115b4e6eb8d0f897edd21144,
title = "Microtubule inhibitor-based antibody–drug conjugates for cancer therapy",
abstract = "The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and limiting toxicity to normal tissue. Microtubules represent a validated oncologic target in a range of tumor types, with a number of anti-microtubule targeting cytotoxic drugs approved for cancer use. The systemic use of potent microtubule-binding agents is limited by their effects in normal cells, which leads to toxicity including myelosuppression and peripheral neuropathy. Linking these agents to monoclonal antibodies may limit toxicity to normal tissues and increase drug concentration in target tissues, also allowing the use of more potent agents which would be too toxic to administer in their unbound form. Two such ADCs have been approved for clinical use and many others are in development. Here we review the characteristics of each of the ADC components that have led to efficacious therapies and discuss some of the tubulin inhibitor-based ADCs in development for cancer therapy.",
keywords = "Antibody–drug conjugate, Microtubule inhibitor, Monoclonal antibody",
author = "Kelsey Klute and Eleni Nackos and Shinsuke Tasaki and Nguyen, {Daniel P.} and Bander, {Neil H.} and Tagawa, {Scott T.}",
year = "2014",
month = "12",
day = "3",
doi = "10.2147/OTT.S46887",
language = "English (US)",
volume = "7",
pages = "2227--2236",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

AU - Klute, Kelsey

AU - Nackos, Eleni

AU - Tasaki, Shinsuke

AU - Nguyen, Daniel P.

AU - Bander, Neil H.

AU - Tagawa, Scott T.

PY - 2014/12/3

Y1 - 2014/12/3

N2 - The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and limiting toxicity to normal tissue. Microtubules represent a validated oncologic target in a range of tumor types, with a number of anti-microtubule targeting cytotoxic drugs approved for cancer use. The systemic use of potent microtubule-binding agents is limited by their effects in normal cells, which leads to toxicity including myelosuppression and peripheral neuropathy. Linking these agents to monoclonal antibodies may limit toxicity to normal tissues and increase drug concentration in target tissues, also allowing the use of more potent agents which would be too toxic to administer in their unbound form. Two such ADCs have been approved for clinical use and many others are in development. Here we review the characteristics of each of the ADC components that have led to efficacious therapies and discuss some of the tubulin inhibitor-based ADCs in development for cancer therapy.

AB - The specificity of monoclonal antibodies represents a potential therapeutic advantage, but their use as single agents in oncology has proven limited to date. The development of antibody-drug conjugates (ADCs) takes advantage of the specificity of the monoclonal antibody and potent cytotoxic effect of chemotherapy, leading to enhanced cytotoxicity in target cells and limiting toxicity to normal tissue. Microtubules represent a validated oncologic target in a range of tumor types, with a number of anti-microtubule targeting cytotoxic drugs approved for cancer use. The systemic use of potent microtubule-binding agents is limited by their effects in normal cells, which leads to toxicity including myelosuppression and peripheral neuropathy. Linking these agents to monoclonal antibodies may limit toxicity to normal tissues and increase drug concentration in target tissues, also allowing the use of more potent agents which would be too toxic to administer in their unbound form. Two such ADCs have been approved for clinical use and many others are in development. Here we review the characteristics of each of the ADC components that have led to efficacious therapies and discuss some of the tubulin inhibitor-based ADCs in development for cancer therapy.

KW - Antibody–drug conjugate

KW - Microtubule inhibitor

KW - Monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=84919329870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919329870&partnerID=8YFLogxK

U2 - 10.2147/OTT.S46887

DO - 10.2147/OTT.S46887

M3 - Review article

C2 - 25506226

AN - SCOPUS:84919329870

VL - 7

SP - 2227

EP - 2236

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -